Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference

Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-g...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Croci, D.O., Rabinovich, G.A.
Formato:	JOUR
Materias:	Angiogenesis anti-VEGF Cancer immunotherapy Galectin Glycans Glycosylation Inflammation glycan glycosyltransferase immunoglobulin G3 immunoglobulin G4 vasculotropin receptor 2 article carcinogenesis catalysis cell adhesion glycosylation human hypoxia lymphocyte proliferation melanoma nonhuman protein binding protein domain protein processing protein protein interaction protein structure sialylation signal transduction tumor microenvironment tumor vascularization upregulation
Acceso en línea:	http://hdl.handle.net/20.500.12110/paper_21624011_v3_n6_p_Croci
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	todo:paper_21624011_v3_n6_p_Croci
record_format	dspace
spelling	todo:paper_21624011_v3_n6_p_Croci2023-10-03T16:39:36Z Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference Croci, D.O. Rabinovich, G.A. Angiogenesis anti-VEGF Cancer immunotherapy Galectin Glycans Glycosylation Inflammation glycan glycosyltransferase immunoglobulin G3 immunoglobulin G4 vasculotropin receptor 2 article carcinogenesis catalysis cell adhesion glycosylation human hypoxia lymphocyte proliferation melanoma nonhuman protein binding protein domain protein processing protein protein interaction protein structure sialylation signal transduction tumor microenvironment tumor vascularization upregulation Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-glycans on VEGFR2 links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in response to VEGF blockade. Fil:Croci, D.O. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_21624011_v3_n6_p_Croci
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	Angiogenesis anti-VEGF Cancer immunotherapy Galectin Glycans Glycosylation Inflammation glycan glycosyltransferase immunoglobulin G3 immunoglobulin G4 vasculotropin receptor 2 article carcinogenesis catalysis cell adhesion glycosylation human hypoxia lymphocyte proliferation melanoma nonhuman protein binding protein domain protein processing protein protein interaction protein structure sialylation signal transduction tumor microenvironment tumor vascularization upregulation
spellingShingle	Angiogenesis anti-VEGF Cancer immunotherapy Galectin Glycans Glycosylation Inflammation glycan glycosyltransferase immunoglobulin G3 immunoglobulin G4 vasculotropin receptor 2 article carcinogenesis catalysis cell adhesion glycosylation human hypoxia lymphocyte proliferation melanoma nonhuman protein binding protein domain protein processing protein protein interaction protein structure sialylation signal transduction tumor microenvironment tumor vascularization upregulation Croci, D.O. Rabinovich, G.A. Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
topic_facet	Angiogenesis anti-VEGF Cancer immunotherapy Galectin Glycans Glycosylation Inflammation glycan glycosyltransferase immunoglobulin G3 immunoglobulin G4 vasculotropin receptor 2 article carcinogenesis catalysis cell adhesion glycosylation human hypoxia lymphocyte proliferation melanoma nonhuman protein binding protein domain protein processing protein protein interaction protein structure sialylation signal transduction tumor microenvironment tumor vascularization upregulation
description	Although blocking vascular endothelial growth factor (VEGF) signaling is clinically beneficial in certain cancers, tumor regrowth in treated patients suggests that compensatory angiogenic programs may limit the efficacy of anti-VEGF treatment. We found that association of galectin-1 with complex N-glycans on VEGFR2 links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in response to VEGF blockade.
format	JOUR
author	Croci, D.O. Rabinovich, G.A.
author_facet	Croci, D.O. Rabinovich, G.A.
author_sort	Croci, D.O.
title	Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_short	Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_full	Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_fullStr	Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_full_unstemmed	Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
title_sort	linking tumor hypoxia with vegfr2 signaling and compensatory angiogenesis: glycans make the difference
url	http://hdl.handle.net/20.500.12110/paper_21624011_v3_n6_p_Croci
work_keys_str_mv	AT crocido linkingtumorhypoxiawithvegfr2signalingandcompensatoryangiogenesisglycansmakethedifference AT rabinovichga linkingtumorhypoxiawithvegfr2signalingandcompensatoryangiogenesisglycansmakethedifference
_version_	1807321185155809280

Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference

Ejemplares similares